Trasylol Class Action Launched in Canada

- by

A class action lawsuit has been launched in Canada, against Bayer Inc. ("Bayer") regarding its drug Trasylol.

Trasylol ("aprotinin") was approved by Health Canada in 1995 for use during heart bypass surgery to help reduce bleeding and the need for blood transfusions. On November 5, 2007, Bayer suspended marketing of Trasylol following results from a clinical trial that suggested an increased risk of death. Use of Trasylol during surgery has been linked to an increased risk of developing cardiovascular or cerebrovascular adverse events, renal dysfunction, or death.

A hearing was scheduled for Wednesday, December 3, 2008, with a panel of experts asked to advise Health Canada on future use of the drug. A review of Trasylol was rushed to print on Tuesday, December 2, 2008 by the Canadian Medical Association Journal in advance of the hearing. The lead author of the review stated that the data did not allow them to identify a subgroup in whom the benefits of Trasylol outweigh the harms.

The Statement of Claim alleges that Bayer failed to adequately warn patients and physicians of the increased risk of serious adverse injury associated with use of Trasylol as compared to safer alternatives.

While it is too early at this stage to quantify the claims of potential class members, it is anticipated that the amount is significant.

Trasylol Clas Action Legal Help

If you or a loved one has suffered damages in this case, please fill in our form on the right and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.

Add Your Comment on This Issue

Fields marked * are mandatory. Please read our comment guidelines before posting.


Note: Your name will be published with your comment.

*Email Address:

Your email will only be used if a response is needed.

*Your Comment:
Request Legal Help